Topical oral dosage forms containing bismuth compounds

Details Topical oral dosage forms containing bismuth compounds Topical oral dosage forms containing bismuth compounds

2005-06-07

2005-06-07

Kishore, Gollamudi S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Food or edible as carrier for pharmaceutical

C424S441000, C424S653000, C514S900000, C514S902000

Reexamination Certificate

active

06902738

ABSTRACT:
Topical oral dosage forms containing bismuth compounds are described, which are useful for treatingH. pyloriand other bacterial infections that cause gastrointestinal disorders and halitosis, as well as for treating ocular and dermal wounds. Methods of employing topical oral dosage forms for treating bacterial infections that cause gastrointestinal disorders and halitosis, and for treating ocular and dermal wounds, are also described.

REFERENCES:
patent: 3011949 (1961-12-01), Bilotti
patent: 3247051 (1966-04-01), Leebrick
patent: 3352689 (1967-11-01), Bilotti
patent: 3577533 (1971-05-01), Rider
patent: 3651208 (1972-03-01), Lauster
patent: 3824006 (1974-07-01), Voit
patent: 3929449 (1975-12-01), Hedrich
patent: 3943258 (1976-03-01), Bahoshy et al.
patent: 3973041 (1976-08-01), DuRoss
patent: 3982023 (1976-09-01), Bahoshy et al.
patent: 4016268 (1977-04-01), Goldenberg et al.
patent: 4055655 (1977-10-01), Maurer et al.
patent: 4118480 (1978-10-01), Williams
patent: 4153685 (1979-05-01), Serfontein
patent: 4180473 (1979-12-01), Maurer et al.
patent: 4208431 (1980-06-01), Friello et al.
patent: 4217368 (1980-08-01), Witzel et al.
patent: 4514421 (1985-04-01), Herschler
patent: 4652444 (1987-03-01), Maurer
patent: 4670245 (1987-06-01), Vasquez et al.
patent: 4680309 (1987-07-01), Maurer
patent: 4800083 (1989-01-01), Hom et al.
patent: 4801454 (1989-01-01), Coveney
patent: 4801608 (1989-01-01), Bos et al.
patent: 4822597 (1989-04-01), Faust et al.
patent: 4879116 (1989-11-01), Fox et al.
patent: 4917899 (1990-04-01), Geoghegan et al.
patent: 4940695 (1990-07-01), Coveney et al.
patent: 4956386 (1990-09-01), McLoughlin et al.
patent: 4965382 (1990-10-01), Furlan
patent: 4975270 (1990-12-01), Kehoe
patent: 5002776 (1991-03-01), Geoghegan et al.
patent: 5013560 (1991-05-01), Stentz et al.
patent: 5017367 (1991-05-01), Stojkoski
patent: 5093342 (1992-03-01), Tomoi et al.
patent: 5192752 (1993-03-01), Chapura et al.
patent: 5196205 (1993-03-01), Borody
patent: 5256684 (1993-10-01), Marshall
patent: 5260304 (1993-11-01), Gergely et al.
patent: 5264222 (1993-11-01), Groenendaal et al.
patent: 5286492 (1994-02-01), Dettmar et al.
patent: 5286497 (1994-02-01), Hendrickson et al.
patent: 5294433 (1994-03-01), Singer et al.
patent: 5304540 (1994-04-01), Blackburn et al.
patent: 5324750 (1994-06-01), Lincoln et al.
patent: 5334582 (1994-08-01), Blackburn et al.
patent: 5352679 (1994-10-01), Ferrieri et al.
patent: 5368845 (1994-11-01), Gaffar et al.
patent: 5372815 (1994-12-01), Hodutu
patent: 5385739 (1995-01-01), Debregeas et al.
patent: 5403830 (1995-04-01), Place
patent: 5425948 (1995-06-01), Olivieri
patent: 5466681 (1995-11-01), Krivan et al.
patent: 5476669 (1995-12-01), Borody
patent: 5514660 (1996-05-01), Zopf et al.
patent: 5536510 (1996-07-01), Tyrpin et al.
patent: 5559096 (1996-09-01), Edwards et al.
patent: 5601848 (1997-02-01), Marshall
patent: 5604212 (1997-02-01), Blank
patent: 5788974 (1998-08-01), D'Amico et al.
patent: 5804549 (1998-09-01), Blackburn et al.
patent: 5834002 (1998-11-01), Athanikar
patent: 5840281 (1998-11-01), Gaffar et al.
patent: 262452 (1963-03-01), None
patent: 65846 (1967-05-01), None
patent: 1963496 (1971-06-01), None
patent: 2012187 (1971-09-01), None
patent: 31 27 639 (1982-08-01), None
patent: 0206627 (1968-12-01), None
patent: 0075992 (1983-04-01), None
patent: 0206626 (1986-12-01), None
patent: 0403048 (1989-06-01), None
patent: 0367484 (1990-05-01), None
patent: 0375063 (1990-06-01), None
patent: 0377477 (1990-07-01), None
patent: 0437294 (1991-07-01), None
patent: 070408 (1968-03-01), None
patent: 102365 (1968-07-01), None
patent: 121072 (1968-12-01), None
patent: 1144915 (1964-03-01), None
patent: 1107655 (1968-03-01), None
patent: 1478742 (1977-07-01), None
patent: 2 195 248 (1988-04-01), None
patent: 2195890 (1988-04-01), None
patent: 2195891 (1988-04-01), None
patent: 2195892 (1988-04-01), None
patent: 8-20543 (1996-01-01), None
patent: WO86/05981 (1986-10-01), None
patent: WO91/03241 (1991-03-01), None
patent: WO92/01457 (1992-02-01), None
patent: WO 97/00668 (1997-01-01), None
“Aldefur”,Unlisted Drugs, Nov. 1970, vol. 22, No. 11, p. 163b.
“Corygest”,Unlisted Drugs, Mar. 1982, vol. 34, No. 3, p. 38.
“Uplex 59051 B”,Rote List, 1976.
“Wismut”, XV 3, pp. 789-791.
1994 Annual Report for Applied Microbiology, Inc.; distributed with notice of Annual Shareholders Meeting which was mailed Feb. 1995.
Abraham et al., “Helicobacter pyloriin its lair: a role in ulcer recurrence?”,Indian Journal of Gastroenterology, 1990, vol. 9, No. 4, pp. 265-269.
Abstracts of PapersGastroenterology, 1986, vol. 88, No. 5, Part 2, pp. 1434, 1585, 1599, 1620.
Abstracts of PapersGastroenterology, vol. 90, No. 5, Part 2, p. 1580.
Abstracts of Papers,Gastroenterology, vol. 92, No. 5, Part 2, p. 1518.
Andersen et al., “Campylobacter pyloriin Peptic Ulcer Disease. II. Endoscopic Findings and Cultivation ofC. pylori.”, Scand. J. Gastroenterol., 1988, pp. 760-764.
Axon, “[chapter] V.Helicobacter pyloritherapy: Effect on peptic ulcer disease”,Journal of Gastroenterology and Hepatology, 1991, vol. 6, pp. 131-137.
Axon, “Campylobacter pylori—Therapy Review”Scand J Gastroenterol, 1989, vol. 24, Supp. 160, pp. 35-38.
Bader, “The Safety Profile of De-Nol®”,Digestion, 1987, vol. 37, Supp. 2, pp. 53-59.
Beil et al., “Studies on the Mechanism of Action of Colloidal Bismuth Subcitrate”,Pharmacology, 1993, vol. 47, pp. 135-144.
Benet, “Safety and Pharmacokinetics: Colloidal Bismuth Subcitrate”,Scand. J. Gastroenterol, 1989, vol. 26. Supp. 185, pp. 29-35.
Bettarello, “Anti-ulcer therapy. Past to present”,Digestive Diseases and SciencesNov. 1985, vol. 30, Supp. 11, pp. 36S-42S.
Bianchi Porro et al., “Comparison of tripotassium dicitrato bismuthate (TDB) tablets and ranitidine in healing and relapse of duodenal ulcers”,The British Society of Gastroenterology, 1984, vol. 25. p. A565, No. F51 (abstract only).
Bianchi Porro et al., “Maintenance therapy with colloidal bismuth subcitrate in duodenal ulcer disease”,Digestion, 1987, vol. 37, Supp. 2, pp. 47-52.
Bianchi Porro et al., “Relapse Rates in Duodenal Ulcer Patients Formerly Treated with Bismuth Subcitrate or Maintained with Cimetidine”,The Lancet, 1984, vol. 2, p 698.
Blaser et al., “Campylobacter enteritis”, New England Journal of Medicine, 1981, vol. 305, pp. 1444-1452.
Bornkessel, “Helicobacter pyloribei Ulkuserkrankungen”,Arneimitteltherapiel, 13.Jahrgang/Heft1/1995, pp. 17-19 (in German).
Borody et al., “High Efficacy, Low Dose Triple Therapy (TT) forHelicobacter pylori(HP)”,Gastroenterology, 1992, vol. 102, No. 4, Part 2, p. A44 (abstract only).
Börsch et al., “Helicobacter pylori”, Pharmacology of peptic ulcer disease, 1991, pp. 106-147.
Bosy et al., “Relationship of Oral Malodor to Periodontitis: Evidence of independence in discrete subpopulations”,J. Periodontal, 1992, vol. 65, No. 1, pp. 37-46.
Bouvet, “Bismuth salts used in gastro-enterology. Data of animal investigations”,Ann. Pharm. Fr, 1980, Voi. 38, pp. 447-454 (in French with English summary).
Boyd et al., “Recurrent ulcer disease”,Gastroenterology Clinics of America. Helicobacter pylori Infection, Mar. 1993, vol. 22. No. 1, pp. 14-42.
Breuer et al., “Epidemiologie und Pathogenese derHelicobacter pylori-infektion”, GASTRO-LIGO Report, Mar./Apr. 1994, pp. 1-5 (in German).
Brogden et al., “Tri-potassium di-citrato bismuthate: a report of its pharmacological properties and therapeutic efficacy in peptic ulcer”,Drugs.1976, vol. 12, pp. 401-411.
CA Abstract AN 1993:421501 of: Nguyen, A. M. H.; Engstrand, L.; Genta, R. M.; Graham, D. Y.; EI-Zaatari, F. A. K., “Detection ofHelicobacter pyloriin dental plaque by reverse transcription-polymerase chain reaction”,J. Clin. Microbiol., 1993, 31(4), 783-7, one page.
Chemical

Affiliated with

Also associated with

Rating

Topical oral dosage forms containing bismuth compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Topical oral dosage forms containing bismuth compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical oral dosage forms containing bismuth compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3510215